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Summary
 
Experimental autoimmune encephalomyelitis (EAE), a demyelinating disease of the central
nervous system, is an animal model of paralyzing human disease, multiple sclerosis. EAE is
readily induced by immunization with myelin basic protein (MBP) in mice transgenic for an
 
ab
 
 T cell receptor (TCR) that is specific for MBP. Subcutaneous injection of p17 (a peptide
consisting of 17 NH
 
2
 
-terminal aminoacids of MBP) in complete Freund’s adjuvant (CFA)
causes paralysis. Induction of paralysis is inhibited by prior intraperitoneal injection of the same
peptide in incomplete Freund’s adjuvant (IFA). In addition, ongoing paralysis is ameliorated by
subsequent intraperitoneal injection of p17 in IFA. Tolerance induction is equally efficient in
Fas-deficient and IL-4–deficient TCR-transgenic mice, suggesting that neither activation-
induced cell death nor differentiation into Th2 type cells plays a role in the tolerance induc-
tion. Tolerance induction by p17 seems to be based on reduction in the responsiveness of anti-
MBP T cells, as documented by lower overall antigen-induced lymphokine production and
proliferation, as well as diminished upregulation of early activation marker CD69 by tolerized
T cells. We propose that continuous encounters of MBP-specific T cells with p17 play a criti-
cal role in the induction and maintenance of tolerance.
ˇ s ´ c
 
I
 
mmunization of susceptible mouse strains with myelin
basic protein (MBP)
 
1
 
 can induce T cell responses that
cause encephalomyelitis and paralysis (experimental au-
toimmune encephalomyelitis, EAE; reference 1), a disease
that is similar to multiple sclerosis (MS) in humans. EAE is
mediated by CD4
 
1
 
 T cells and it can be adoptively trans-
fered by in vitro–activated, MBP-specific T cell clones into
either athymic or euthymic animals (2, 3). The majority of
T cell clones capable of inducing EAE has been found to
produce IFN-
 
g
 
, together with other Th1-type cytokines
(4, 5). On the other hand, most T cell clones that produce
IL-4 or IL-10, i.e., Th2-type cytokines, are nonencephali-
togenic (4, 5). Furthermore, examination of spinal cords
from diseased animals has revealed the presence of mRNA
for IFN-
 
g
 
, TNF-
 
a
 
, and IL-2, whereas mRNA for IL-10
appeared at the time of clinical remissions (6). These results
have suggested that EAE could be induced by T cells pro-
ducing Th1-type cytokines and prevented and/or amelio-
rated by T cells producing Th2-type cytokines.
The ideal therapy of MS and other chronic inflammatory
autoimmune diseases, such as diabetes or rheumatoid arthritis,
would be selective inactivation, elimination, or functional
deviation of the disease causing T cells. Various approaches
have been used to down regulate antigen-specific responses
in EAE. Vaccination of rats with low numbers of encepha-
litogenic T cells can result in resistance to EAE induced by
higher numbers of the same cells (7). Also, immunization
with peptide derived from TCRs of encephalitogenic clones
could convey resistance to EAE induction (8). Rats fed
with MBP do not develop EAE after immunization with
MBP emulsified in CFA (9). It has been suggested that all
these manipulations induce regulatory cells, which in turn
control EAE. On the other hand, administration of mono-
clonal antibodies against either TCRs of encephalitogenic
clones or against class II MHC molecules prevents EAE by
abolishing antigen recognition (10, 11). Administration of
altered as well as unaltered MBP-derived peptides could
prevent EAE induction or reverse the ongoing EAE (12–
15). When administered at the time of immunization with
MBP, MBP-derived peptides with one or two amino acid
substitutions could prevent EAE development (14, 15).
The peptide with two amino acid substitutions could bind
MHC class II, A
 
u
 
 molecule with much higher affinity than
the unaltered peptide, but could not stimulate proliferation
of the MBP-specific T cells (15). However, the peptide
with only one amino acid substitution (4A) could both
bind A
 
u
 
 molecule and stimulate MBP-specific T cells in
 
1
 
Abbreviations used in this paper:
 
 EAE, experimental autoimmune encepha-
lomyelitis; MBP, myelin basic protein; MS, multiple sclerosis; SCH, spi-
nal cord homogenate; TR
 
1
 
, TCR-transgenic mice.
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vitro (14). Whereas MHC blockade appears to be the
mechanism of EAE prevention by the peptide with two
amino acid substitutions, this explanation is not applicable
to EAE prevention by the peptide with the single amino
acid substitution. Finally, an MBP-derived peptide was en-
cepalitogenic when administered subcutaneously in CFA
but prevented EAE when it was injected intraperitoneally
in IFA (12). It has been suggested that the administration of
peptide in IFA induces differention of potentially encepha-
litogenic T cells into nonencephalitogenic, possibly protec-
tive Th2 (16). However, other data support the alternative
explanation that upon MBP/IFA administration, MBP-
specific T cells become anergic (12). The state of anergy
develops when TCRs are engaged in the absence of a sec-
ond signal from costimulatory proteins. The T cells do not
produce IL-2 and do not proliferate even when they are
restimulated by professional APCs which provide the sec-
ond signal (17).
To investigate the mechanisms of tolerance induced by
administration of antigen in IFA, as well as its potential
clinical application, we used an EAE model in TCR-trans-
genic mice (TR
 
1
 
) (18). Our data indicate that administra-
tion of MBP-derived peptides in IFA does not induce pro-
tective T or B cells but rather leads to the downregulation
of encephalitogenic T cell functions.
 
Materials and Methods
 
Mice and EAE Induction.
 
Mice expressing a transgenic TCR
specific for A
 
u
 
 and p17, an acetylated peptide corresponding to
the 17 NH
 
2
 
-terminal amino acids of MBP, were generated as de-
scribed (18). The TCR-transgenic mice were crossed with RAG-
1–deficient (19) and IL-4–deficient mice (20) to produce TCR-
transgenic mice homozygous or heterozygous for RAG-1 and
IL-4 deficiency, respectively. The TCR-transgenic mice are re-
ferred to as TR
 
1
 
 mice and the crosses of these mice with RAG-
1
 
2
 
 mice are called TR
 
2
 
 mice (T stands for transgenic TCR and
R for RAG-1). To obtain mice deficient in Fas expression, TCR
transgenic mice were crossed with lpr mutant mice (Jackson Lab-
oratories, Bar Harbor, ME). All mice were housed in sterile cages
and provided with sterile food and water. Transgenic TCR ex-
pression was determined by flow cytometry using anti-V
 
b
 
8–
FITC and anti-CD4–PE antibodies (PharMingen, San Diego,
CA). RAG-1 gene expression was determined by flow cytometry
using anti-CD3–FITC and anti-B220–PE antibodies (PharMin-
gen) or by PCR using three oligonucleotides, two specifically
spanning the genomic disruption of RAG-1 gene and the third
within the neomycin resistance marker. The disruption of the IL-4
gene was determined by PCR using three oligonucleotides, two
specifically spanning the genomic disruption of IL-4 and the third
within the neomycin resistance marker. The presence of lpr mu-
tation was determined by PCR, using three oligonucleotides, two
specifically spanning the insertional mutation of the Fas gene and
the third within the insertion (21).
To induce EAE, mice were injected subcutaneously with 200
 
m
 
g of p17 emulsified in CFA (GIBCO BRL, Gaithersburg, MD),
in a total volume of 0.1 ml. 1 and 3 d after the immunization, the
mice were injected intraperitoneally with 200 ng of pertussis
toxin (List Biological Laboratory, Campbell, CA) in PBS. EAE
was scored as follows: level 1, limp tail; level 2, partial hind leg
paralysis; level 3, total hind leg or partial hind and front leg paral-
ysis; level 4, total hind leg and partial front leg paralysis; level 5,
moribund. Animals were observed daily and killed when they
reached level 4–5. All work was performed in accordance with
the MIT guidelines for animal use and care.
Spinal cord homogenate (SCH) was prepared by mixing 1 mg
of spinal cord per 0.15 ml PBS and addition of the same volume
of IFA. The emulsion was prepared using sonification.
 
Lymphokine Production.
 
The assay employed to test lympho-
kine production was a modification of the ELISPOT assay, which
allows us to detect the production of lymphokines in vitro with-
out the need for multiple stimulations. Flat-bottomed 96-well
plates were incubated for at least 12 h with purified anti-IL-2,
anti-IL-4, anti-IFN-
 
g
 
, and anti-TNF-
 
a
 
 capture antibodies at 4
 
8
 
C
(all antibodies used in this assay were from PharMingen). Un-
bound antibodies were washed away with PBS and T cell stimu-
lation was carried out in the coated wells. Various numbers of pu-
rified V
 
b
 
8.2
 
1
 
CD4
 
1
 
 spleen cells from RAG-1–deficient mice
transgenic for the anti-MBP TCR (TR
 
2
 
 mice) were stimulated
with irradiated (2,200 rads) total spleen cells (7 
 
3
 
 10
 
5
 
 per well)
and p17 (50 
 
m
 
g/ml). After 60 h, the plates were washed with
PBS, 0.05% Tween-20 (Sigma Chemical Co., St. Louis, MO).
Then, biotinylated anti-IL-2, anti-IL-4, anti-IFN-
 
g
 
, or anti-
TNF-
 
a
 
 detection antibodies were added, and incubated for 2 h at
room temperature. After extensive washing, the plates were incu-
bated with streptavidin–horseradish peroxidase (Southern Bio-
technology Associates, Birmingham, AL). After 20 min, the plates
were washed again and incubated with the substrate, 3,3
 
9
 
,5,5
 
9
 
-
tetramethyl-benzidine (Sigma Chemical Co.). The reaction was
stopped with 2 M H
 
2
 
SO
 
4
 
 and read at 450 nm.
 
Cell Proliferation.
 
Purified V
 
b
 
8.2
 
1
 
CD4
 
1
 
 splenic T cells (3 
 
3
 
10
 
4
 
 per well) from RAG-1–deficient mice, transgenic for anti-
MBP–specific TCR were incubated in 96-well plates in the ab-
sence or presence of various doses of p17. Irradiated (2,200 rads)
PL/J spleen cells (7 
 
3
 
 10
 
5
 
 per well) were added as APC. After 48 h,
the plates were pulsed with [
 
3
 
H]thymidine for 16 h, cells were
harvested, and the incorporated radioactivity counted.
 
Adoptive Cell Transfer.
 
Spleen cells from either IFA- or p17/
IFA-pretreated mice were isolated and injected intravenously into
either RAG-1–deficient (H-2
 
u
 
) or PL/J mice that had been le-
thally irradiated (900 rads) and reconstituted with bone marrow
cells from RAG-1–deficient (H-2
 
u
 
) mice. When PL/J mice were
used as recipients, spleen cell transfer was performed 2 wk after
the lethal irradiation and bone marrow reconstitution. The num-
ber of transfered cells was adjusted to contain 3 
 
3
 
 10
 
6
 
 V
 
b
 
8
 
1
 
CD4
 
1
 
 T cells.
 
Flow Cytometry.
 
Cells were stained with directly labeled anti-
bodies: 
 
z
 
1 
 
3
 
 10
 
6
 
 cells were incubated with antibodies for 30 min
at 4
 
8
 
C. Cells were washed and analysed with FACScan
 
Ò
 
 (Becton
Dickinson, Mountain View, CA) for FITC and PE staining.
Dead cells were gated out using propidium iodine. All antibodies
were purchased from Pharmingen.
 
Results
 
Intraperitoneal Administration of the Encephalitogenic Peptide
p17 in IFA Both Prevents and Cures EAE.
 
The transgenic
TCR specific for A
 
u
 
 and p17, an acetylated peptide corre-
sponding to the 17 NH
 
2
 
-terminal amino acids of MBP, is
expressed by most peripheral T cells in TR
 
1
 
 mice (18).
Subcutaneous injection of p17 in CFA, accompanied by
intraperitoneal injection of pertussis toxin, induces severe 
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paralysis in 90–100% of these mice. However, only mild or
no paralysis at all developed when the mice received p17 in
IFA intraperitoneally 2 wk before the disease-inducing
treatment (Fig. 1 
 
A
 
). To address the role of nontransgenic
TCR-expressing lymphocytes in the tolerance induction,
we crossed TR
 
1
 
 mice with RAG-1–deficient mice, to
produce TR
 
2
 
 mice in which the only mature lymphocytes
present are those expressing the transgenic TCR (18, 19).
Intraperitoneal injection of p17 in IFA prevented paralysis
in TR
 
2
 
 mice that would have been induced by injection of
p17 in CFA and pertusis toxin (Fig. 1 
 
B
 
). Thus, tolerance
induction in this model did not depend on nontransgenic
TCR-expressing T cells such as anti-clonotypic regulatory
CD4 or CD8 T cells or on B cells, the latter of which have
been suggested to be tolerogenic APC in other tolerance
induction models (22, 23). Dose titration experiments have
shown that as little as 20 
 
m
 
g of p17 injected intraperito-
neally in IFA provided protection against EAE (data not
shown). The full protection induced by 100 
 
m
 
g of p17 in-
jected intraperitoneally in IFA lasted at least 2 mo after the
injection of the tolerogen (data not shown).
Next, we investigated whether intraperitoneal injection
of p17 in IFA could prevent the progression of paralysis in
the transgenic mice after EAE induction. When half of the
mice developed signs of paralysis, both sick and still healthy
mice were randomly divided into two groups and injected
intraperitoneally with IFA emulsion, with or without p17.
In contrast with mice that did not receive p17, which de-
veloped severe EAE, p17-injected mice rapidly recovered
(Fig. 1 
 
C
 
). Thus, the p17/IFA treatment seems to be effec-
tive in both preventing and curing EAE. We were also able
to reverse the course of p17/CFA-induced EAE by inject-
ing mice intraperitoneally with whole SCH in IFA. Mice
injected with SCH corresponding to 100 
 
m
 
g of dry matter
per mouse were almost completely protected from EAE,
whereas mice receiving PBS/IFA developed severe EAE
(data not shown).
A series of experiments was performend to determine
whether the protective effect of p17/IFA was due to any of
the previously suggested mechanisms of tolerance induc-
tion, such as the deletion of T cells (24), the induction of
unresponsiveness (12, 17), or the deviation of a pathogenic
Th1 response to a nonpathogenic or disease-protective
Th2 response (16).
 
Anti-MBP–specific T Cells Are Present in Mice After p17/
IFA Administration.
 
Flow cytometric analysis did not re-
veal any deletion of MBP-specific T cells in lymph nodes
or in the spleen during the course of tolerance and disease
induction (Fig. 2). Similar results were observed in TR
 
2
 
mice in which all T cells express the transgenic TCR (data
not shown). A small reduction in the percentage of the
transgenic TCR-expressing cells was accompanied by an
increase in the total spleen cell number (1.5–3-fold) in
p17/IFA-pretreated mice (data not shown). Thymectomy
7 d before tolerance induction did not lead to a significant
reduction in the number of the transgenic TCR-expressing
cells as compared with nonthymectomized, tolerized mice
(data not shown). This excludes the possibility that T cell
deletion did occur but was masked by the appearance of
new thymic emigrants in the periphery. Finally, adoptive
transfer experiments showed that no more than than 10
 
5
 
transgenic TCR-expressing cells had to be transferred into
RAG-1–deficient hosts to make them susceptible to EAE
Figure 1. (A) Pretreatment of mice transgenic for an MBP-specific
TCR (TR1) with p17 (a peptide consisting of the 17 NH2-terminal
amino acids of MBP) in IFA prevents EAE. On day 214, TR1 mice
were injected intraperitoneally with either 500 mg of p17 (closed squares)
or PBS (open squares), emulsified in IFA. On day 0, all mice were injected
subcutaneously with p17/CFA and intraperitoneally with pertussis toxin.
Starting with day 6, the mice were evaluated for EAE and scored as fol-
lows: level 1, limp tail; level 2, partial paralysis of hind legs; level 3, com-
plete paralysis of hind legs or partial paralysis of hind and front legs; level
4, complete paralysis of hind legs and partial paralysis of front legs; level 5,
moribund. Mice were killed after reaching level 4–5 of EAE. The results
shown are representative of five similar experiments with 5 to 9 mice per
group. Data are expressed as a mean of EAE scores of all the mice in the
group. (B) Pretreatment of RAG-1–deficient mice transgenic for the
MBP-specific TCR (TR2) with p17 in IFA prevents EAE. Mice were
pretreated with p17 (closed squares) or PBS (open squares), as described in A.
On day 0, all mice were injected subcutaneously with p17/CFA and in-
traperitoneally with pertussis toxin, and EAE was scored daily as described
above. The results shown are representative of three similar experiments
with 5 to 11 mice per group. (C) TR1 mice recover from EAE after in-
traperitoneal administration of p17 in IFA. The mice were injected sub-
cutaneously with p17/CFA and intraperitoneally with pertussis toxin. On
day 5, mice which developed the first signs of EAE were injected intra-
peritoneally, with either 500 mg of p17 (closed squares) or PBS (open
squares), emulsified in IFA. On day 6, the rest of the mice (some showing
the first signs of EAE and some still appearing healthy), were injected
with either p17 or PBS emulsified in IFA (the arrows indicate the time of
injection). In total, half of the mice have had developed EAE when they
received the treatment. Mice were scored daily for the level of paralysis as
described above. The results shown are representative of four similar ex-
periments with 6 to 11 mice/group. 
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induction (data not shown). This finding indicates that a
small reduction in the number of anti-MBP–specific T cells
cannot explain the protective effect of p17/IFA administra-
tion. Although a significant T cell deletion was not ob-
served in the peripheral lymphoid organs of p17/IFA-
treated mice, Fas-mediated, activation-induced cell death
could have occurred in the central nervous system, upon
recognition of antigen by T cells. To test this possibility,
we crossed TR
 
1
 
 mice with lpr mutant mice that are defi-
cient in the expression of Fas molecule (21). Mature T cells
of these mice have a defect in antigen-stimulated T cell
death (25). The capacity of p17/IFA to induce EAE resis-
tance was than tested in TR
 
1
 
 mice that were homozygous
or heterozygous for the lpr mutation. When administered
intraperitoneally 6 d after EAE induction, p17/IFA pre-
vented paralysis in both Fas-deficient and normal mice
(Fig. 3), indicating that Fas-mediated cell death was not re-
sponsible for the failure of tolerized mice to develop EAE.
 
Anti–MBP-specific T Cells Do Not Differentiate into Th2
Type After p17/IFA Administration.
 
Because MBP-specific
T cells are not deleted, antigen-induced functional changes
must account for the prevention and/or reversal of tissue
destruction and paralysis after p17/IFA administration. It
has been suggested that tissue destruction is mediated by a
Th1-type response, whereas a Th2-type response is non-
pathological or even protective (26–30). Therefore, we at-
tempted to prevent paralysis, using the p17/IFA tolerance
induction protocol, in mice produced by a cross between
TR
 
1
 
 mice and IL-4–deficient mice (20). IL-4 has been
shown to be neccessary for Th2 responses in vitro as well as
in vivo (20, 31–33). Intraperitoneal injection of p17 in IFA
prevented paralysis in TR
 
1
 
, IL-4–deficient mice (Fig. 4 
 
A
 
).
We could also show that the intraperitoneal injection of
p17/IFA 6 d after the injection of p17/CFA and pertussis
toxin prevented paralysis in TR
 
1
 
, IL-4–deficient mice (Fig.
4 
 
B
 
). Thus, IL-4 does not seem to play an essential role,
neither in the induction of tolerance to prevent devel-
opment of EAE nor in reversing the course of develop-
ing EAE.
To examine the possibility that protective Th2 were
generated in the absence of IL-4 (34), we tested the pattern
of lymphokine production by splenic (Fig. 5 
 
A
 
) and lymph
node (data not shown) T cells from tolerized and untoler-
ized mice. 2 wk after the intraperitoneal injection of IFA or
p17/IFA, the mice were injected subcutaneously with
MBP in CFA and intraperitoneally with pertussis toxin. 4 d
Figure 2. Transgenic TCR-expressing cells are not deleted in p17/
IFA-treated mice. Mice were injected intraperitoneally with 500 mg p17/
IFA (A, C, E, G, I) or PBS/IFA (B, D, F, H, J) on day 214, and with
200  mg p17/CFA subcutaneously and 400 ng pertussis toxin intra-
peritoneally on day 0. Splenic cells were stained with anti-CD4–PE and
anti-Vb8–FITC antibodies, and analyzed by FACSÒ. Cells were analyzed
on days 29 (A and B), day 24 (C and D), and day 0, before EAE induc-
tion (E and F), as well as day 1 (G and H) and day 5 (I and J) after EAE
induction.
Figure 3. EAE can be prevented in lpr mutant mice transgenic for anti-
MBP–specific TCR. lpr-mutant, TR1 mice were injected subcutane-
ously with p17/CFA and intraperitoneally with pertussis toxin. On day 6,
mice were injected intraperitoneally with either 500 mg p17 (closed
squares) or PBS (open squares) emulsified in IFA. Six mice in each group
were scored daily for the level of paralysis as described in Fig. 1 A.511 Maru i  and Tonegawa s ˇ ´ c
later, lymphokine production was measured by the modi-
fied ELISPOT assay. T cells from the p17/IFA-injected
mice produced lower levels of all lymphokines tested as
compared with T cells from IFA-injected mice. Although
the reduction of IFN-g was most pronounced, the levels of
IL-2, IL-4, and TNF-a were also reduced (Fig. 5 A). The
level of production of these lymphokines was also reduced
on days 1 and 7 after the administration of p17/CFA and
pertussis toxin (data not shown). The levels of IL-10 and
IL-5 were low in nontolerized mice and were further re-
duced in tolerized mice (data not shown). T cells from the
tolerized mice also proliferated less vigorously after in vitro
stimulation with p17 and splenic APCs than T cells from
nontolerized mice (Fig. 5 B). The impaired proliferative re-
sponse was not rescued by addition of exogenous IL-2. Fi-
nally, in vivo upregulation of the early activation marker
CD69, which was observed in nontolerized mice 24 h after
EAE induction, was almost entirely absent in tolerized
mice (Fig. 5 C). These data suggest that the function of
pathogenic anti-MBP T cells is downregulated in mice
treated with p17 in IFA, rather than that the development
of these T cells is directed toward a nondestructive, Th2
type response. However, we cannot exclude the possibility
that protection resulted from subtle changes in the ratio of
pro- and antiinflammatory cytokine production.
Tolerized T Cells Regain Encephalitogenicity in the Absence of
Tolerizing Form of the Antigen. To test whether T cells
from tolerized mice remain unable to induce EAE in the
absence of p17, we transferred them into tolerogen-free
hosts. As recipients, we used either RAG-1–deficient (H-2u)
mice or PL/J mice that had been lethally irradiated and re-
constituted with RAG-1–deficient (H-2u) bone marrow.
When 3 3 106 p17-specific T cells from tolerized or non-
Figure 4. EAE can be prevented in IL-4–deficient mice transgenic for
the MBP-specific TCR. (A) IL-4–deficient, TR1 mice were injected in-
traperitoneally with p17 (closed squares) or PBS (open squares) on day 214,
as described in Fig. 1 A. On day 0, all mice were injected subcutaneously
with p17/CFA and intraperitoneally with pertussis toxin, and the level of
EAE was scored daily as described in Fig. 1. Similar results were obtained
in two independent experiments with 8 to 10 mice per group. (B) Intra-
peritoneally injected p17/IFA prevents EAE in IL-4–deficient TR1 mice
when administered during the course of EAE development. IL-4–defi-
cient TR1 mice were injected subcutaneously with p17/CFA and intra-
peritoneally with pertussis toxin. On day 6, mice were injected intraperi-
toneally with either 500 mg of p17 (closed squares) or PBS (open squares)
emulsified in IFA. Eight mice in each group were scored daily for the
level of paralysis as described in Fig. 1 A.
Figure 5. Anti-MBP–specific T cells from tolerized mice have lower
responsiveness than the cells from nontolerized mice. On day 214, TR2
mice were injected intraperitoneally with either 500 mg of p17 or PBS,
emulsified in IFA. On day 0, all the mice were injected subcutaneously
with 200 mg of p17 emulsified in CFA and intraperitoneally with 400 ng
of pertussis toxin. Antigen-induced lymphokine production and prolifera-
tion by p17-specific T cells from p17- or PBS-pretreated mice was ana-
lyzed on day 4, after p17/CFA and pertusis toxin injection. Splenic T
cells from either IFA- or p17/IFA-pretreated mice were purified using
anti-CD4–bound magnetic microbeads (Mylteni Biotec GmbH, Ger-
many) and purity was checked by FACSÒ analysis (usually .80%). The
responder cell number was adjusted so that the same number of transgenic
TCR-expressing cells was tested in various groups for lymphokine pro-
duction and proliferation. (A) Production of IL-2, IL-4, IFN-g, and
TNF-a by T cells from tolerized (bars with wide stripes) or nontolerized
(bars with narrow stripes) mice was determined using a modification of
ELISPOT assay. The results shown are representative of five similar ex-
periments. (B) T cells from p17/IFA-pretreated mice (circles) or PBS/IFA-
pretreated mice (squares) were stimulated with various amounts of p17, in
the absence (open symbols) or presence (closed symbols) of 100 IU/ml IL-2.
[3H]thymidine incorporation was measured after 48 h of culture. The re-
sults shown are representative of three similar experiments. (C) In vivo
upregulation of the early activation marker CD69 on T cells from p17- or
PBS-pretreated mice was determined. On day 1 after MBP/CFA and
pertussis toxin injection, spleen cells were stained with anti-CD69–PE
and anti-Vb8–FITC antibodies, and analyzed by FACSÒ.512 Tolerance Induction with Myelin Basic Protein–derived Peptide
tolerized TR2 mice were transferred into the p17-free re-
cipients, all mice developed lethal EAE (Fig. 6). Mice that
received T cells from tolerized donors developed EAE with
a delay of 2–3 d, in comparison with the mice that received
T cells from nontolerized donors. However, the severity of
EAE was the same in both groups of mice. Next, we deter-
mined whether the tolerant state of the transferred T cells
could be maintained if the host was treated with p17. Mice
that received cells from tolerized mice were injected intra-
peritoneally with p17/IFA (500 mg per mouse), 5 d after
EAE induction. Although all mice receiving tolerized cells
only developed EAE, mice that received tolerized cells and
p17/IFA remained healthy (Fig. 6). These results indicate
that the continuous presence of p17 was necessary for the
maintanence of tolerance.
Several experiments were performed to define better the
mode of antigen administration that is required for toler-
ance induction. In the above-described experiments p17
induced EAE when administered subcutaneously in CFA
but prevented disease induction or reversed ongoing dis-
ease when administered intraperitoneally in IFA. To deter-
mine whether the different effects of p17 arose from the
difference in the adjuvant or from differences in the routes
of administration, or from both, we injected p17 in IFA
subcutaneously rather than intraperitoneally into TR1 mice.
2 wk later, we tested whether these mice were resistant to
EAE induction. Mice injected with p17/IFA subcutane-
ously developed paralysis after the challenge with p17/CFA
and pertussis toxin (Fig. 7 A; data not shown). However,
tolerance could be achieved if the mice were injected sub-
cutaneously with p17 in IFA five times within 2 wk. The
total dose of p17 was the same in the multiple- and in the
single-injection protocol. Finally, we injected mice intra-
peritoneally with p17 in CFA rather than IFA 6 d after the
subcutaneous injection of p17/CFA and pertussis toxin. In
contrast with mice intraperitoneally injected with CFA,
mice injected with p17/CFA did not develop paralysis
(Fig. 7 B).
Discussion
The present study shows that clinically relevant tolerance
can be induced in TCR-transgenic mice by a single intra-
peritoneal or repeated subcutaneous injections of peptide in
IFA. Whereas subcutaneous administration of the MBP-
derived peptide p17 in CFA induced acute EAE, all mice
were protected against this mode of disease induction by
pretreatment with the same peptide in IFA. Because of the
large number of p17-specific T cells in the TCR-transgenic
mice, it seemed unlikely that all potentially disease-causing
cells were deleted or rendered unresponsive by a single in-
Figure 6. Tolerized cells regain encephalitogenicity upon transfer into
tolerogen-free host. TR2 mice were injected intraperitoneally with either
PBS/IFA or 500 mg p17/IFA. 3 wk later, spleen cells from either p17- or
PBS-pretreated mice, containing 3 3 106 Vb81CD41 T cells, were in-
jected intravenously into lethally irradiated (900 rads), RAG-1–deficient
bone marrow–reconstituted PL/J mice. 1 d after the spleen cell transfer,
EAE was induced as described in Fig. 1. Half of the mice that received the
cells from p17/IFA-pretreated donors also received 500 mg p17/IFA, in-
traperitoneally, 5 d after EAE induction. Similar results were obtained in
two independent experiments with five to eight mice per group.
Figure 7. (A) A single intraperitoneal or five subcutaneous, but not a
single subcutaneous injection of p17 in IFA prevents EAE. On day 214,
mice were either left untreated (open squares) or injected with 500 mg of
p17 emulsified in IFA intraperitoneally (closed squares) or subcutaneously
(circles). The fourth group of mice (triangles) was injected subcutaneously
five times with 100 mg of p17/IFA, on days 214, 211, 28, 25, and 22.
(The total amount of p17 injected into these mice was 500 mg.) On day
0, all mice were injected subcutaneously with p17/CFA and intraperito-
neally with pertussis toxin. Eleven mice in each group were scored daily
for signs of paralysis, as described in Fig. 1 A. (B) Intraperitoneal adminis-
tration of p17 in CFA prevents EAE. TR1 mice were injected subcutane-
ously with p17/CFA and intraperitoneally with pertussis toxin. On day 6,
mice were injected intraperitoneally with either 100 mg of p17 (closed
squares) or PBS (open squares) emulsified in CFA. Mice were scored daily
for the level of EAE as described in Fig. 1 A. The results shown are repre-
sentative of four similar experiments with five to eight mice per group.513 Maru i  and Tonegawa s ˇ ´ c
jection of 100 mg peptide in IFA. Indeed, in a previous
study a significant reduction of antigen-induced T cell pro-
liferation could not be induced in TCR transgenic mice by
a single intraperitoneal injection of peptide in IFA (35).
Therefore, we suspected that in our experiment the pep-
tide/IFA administration induced regulatory cells that had a
protective effect. However, this does not seem to be the
case. Tolerance was readily induced in crosses of TCR-
transgenic mice with RAG-1–deficient mice, indicating
that neither B cells nor gd T cells nor antiidiotypic T cells
were required for tolerance induction. If regulatory cells
were involved, they must be transgenic TCR-expressing
CD4 T cells. It is conceivable that, depending on the mode
of immunization, the same transgenic TCR-expressing cells
develop either into disease-causing cells that are known to
be Th1 or into protective cells. In our laboratory and in
others, it has been found that the T cells that cause EAE are
Th1 (5, 36, 37). Because Th1 and Th2 have opposite and
mutually suppressive functions, Th2 have frequently been
assumed to protect against EAE and other Th1-mediated
autoimmune diseases (38). Indeed, in previous studies it
was found that intraperitoneal injection of antigen in IFA
or intravenous injection of antigen in PBS prevented Th1
responses, whereas Th2 were activated to produce IL-4
(39, 40). Thus, in the present study, administration of the
peptide in IFA might have induced Th2 that either pre-
vented the induction of disease-causing Th1 or that inhib-
ited the disease-causing action of Th1. This possibility is
highly unlikely for several reasons. First, we were able to
induce tolerance in IL-4–deficient mice that are defective
in Th2 responses (20). Second, T cells from tolerant mice
produced lower amounts of not only the Th1 cytokine
IFN-g, but also the Th2 cytokine IL-4. Third, recent stud-
ies in this laboratory have shown that Th2 did not have a
protective effect against Th1-mediated EAE but rather in-
duced EAE themselves when injected into immunodefi-
cient RAG-1 knockout mice (36). This latter finding is in
line with a previous report by others, which showed that in
nonobese diabetic mice, Th2 clones, although not diabeto-
genic, induced insulitis and were not able to prevent diabe-
tes induction by Th1 clones (30).
These findings do not support an involvement of regula-
tory cells in the protection against EAE. The observed pro-
tection must be due to the induction of anergy and/or de-
letion of all or almost all transgenic TCR-expressing cells.
However, in our present study, there was no evidence for
the disappearance of a large fraction of the transgenic TCR
expressing cells after peptide/IFA administration even if the
mice were thymectomized briefly before tolerance induc-
tion. In previous studies, peptide-induced tolerance was as-
sociated with the elimination of peptide-specific T cells in
some cases (41, 42), but not in others (12, 43). Whether
the T cells are eliminated or rendered unresponsive appears
to depend mainly on the peptide dose and the route of ad-
ministration. T cell deletion has mainly been observed after
intravenous or intraperitonel administration of high doses
of peptide. Similar to our findings, Falb et al. did not ob-
serve a cross elimination of T cells in mice expressing a
transgenic TCR for a cytochrome c–derived peptide after
thymectomy and intravenous injection of 10, 50, and 100
mg peptide on days 1, 4, and 7 (43). Using the same TCR-
transgenic mice Singer and Abbas did observe deletion of T
cells 7 d after three intraperitoneal injections of 100 mg cy-
tochrome c–derived peptide (42). The deletion was Fas
mediated, because it was not observed in crosses of the
TCR-transgenic mice with Fas-deficient (lpr) mice, which
have a defect in antigen-induced apoptosis of T cells (25).
To examine the possibility that Fas-mediated elimination
of T cells within the brain lesions was responsible for the
protective effect of peptide/IFA administration, we also
crossed our TCR transgenic mice with lpr mice. Protec-
tion against EAE was readily induced in Fas-deficient
TCR-transgenic mice, indicating that Fas was not required
for tolerance induction by peptide/IFA administration.
Similarly, others have shown that tolerance to chicken
OVA is inducible in lpr mice by intraperitoneal administra-
tion of the antigen in IFA (44). Although we cannot ex-
clude the possibility that some p17-specific T cells were
deleted via the action of apoptosis-inducing factors other
than the Fas ligand such as TNF-a, it is clear that the vast
majority of the transgenic TCR expressing cells was still
present in peptide/IFA-treated mice. Thus, the most likely
explanation for the protective effect of peptide/IFA admin-
istration is the induction of anergy. In vivo, the early acti-
vation marker CD69 was not upregulated and, in vitro,
both cytokine production and proliferation in response to
p17 was severely reduced. The proliferative response could
not be rescued by the addition of exogenous IL-2. In stud-
ies of adoptively transferred T cells from TCR-transgenic
mice, Kearney et al. also found that administration of anti-
gen in IFA-diminished proliferation and IL-2 production
in vitro in response to antigen (35). The lack of IL-2 pro-
duction is a common observation in anergic T cells (17, 36,
45). Lack of responsiveness of anergic T cells to IL-2 has
also been observed, although less frequently (46).
In the present study, anergy could be induced by several
modes of administration of peptides. Although a single intra-
peritoneal injection of p17 in IFA was sufficient, several
consecutive, subcutaneous injections were required to achieve
protection against EAE. Protection was also achieved by a
single intraperitoneal injection of p17 in CFA. This was
quite unexpected, because CFA induces an inflammatory
response that could prevent tolerance induction (47). In
contrast with many other studies we were unable to induce
anergy by intravenous administration of the peptide. Prob-
ably depending on the structure, some intravenously in-
jected peptide are rapidly eliminated without reaching any
sites where anergy could be induced in the recirculating T
cell pool. It is conceivable that anergy induction requires
the continuous presence of the peptide at sites that are fre-
quently encountered by recirculating T cells. Interestingly,
after a single intraperitoneal injection of p17/IFA T cell an-
ergy, as revealed by protection against EAE induction,
lasted for up to 2 mo. When anergic T cells from tolerant
mice were transferred into tolerogen-free recipients, the
anergy was rapidly lost and EAE could readily be induced514 Tolerance Induction with Myelin Basic Protein–derived Peptide
by immmunzation with p17 in CFA. This implies that the
peptide must persist in tolerant mice as long as the toler-
ance is observed. Further experiments are required to de-
termine where in the body the peptide needs to localize for
anergy induction and which cells are required for the pre-
sentation by MHC class II molecules.
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